High mRNA levels of AREG predicted for longer survival in patients with KRAS wild-type (median survival 33 vs. 15 months, p=0.0005, Figure 2), but not in KRAS mutant tumours (median survival 22 vs. 17 months, p=0.64). Here, KRAS is linked to neoplasm.